Platelet-derived TGF-β and direct platelet-tumor cell contraction can synergistically activate the TGF-β/Smad and NF-κB pathways in cancer cells, exhibiting an aggressive mesenchymal phenotype and enhanced metastasis in vivo (85). Here, TGFB1 is linked to neoplasm.